<- Go Home
Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Market Cap
EUR 3.3B
Volume
98.6K
Cash and Equivalents
EUR 46.1M
EBITDA
EUR 194.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 467.4M
Profit Margin
62.40%
52 Week High
EUR 80.20
52 Week Low
EUR 45.52
Dividend
1.45%
Price / Book Value
5.84
Price / Earnings
24.87
Price / Tangible Book Value
6.17
Enterprise Value
EUR 3.4B
Enterprise Value / EBITDA
16.88
Operating Income
EUR 172.7M
Return on Equity
25.01%
Return on Assets
12.50
Cash and Short Term Investments
EUR 47.7M
Debt
EUR 129.3M
Equity
EUR 574.7M
Revenue
EUR 749.0M
Unlevered FCF
EUR 9.0M
Sector
Pharmaceuticals
Category
N/A